Thousand Oaks, CA, United States of America

Timothy Hopper

USPTO Granted Patents = 7 

Average Co-Inventor Count = 10.9

ph-index = 3

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2023-2025

Loading Chart...
7 patents (USPTO):

Title: The Innovative Contributions of Timothy Hopper

Introduction

Timothy Hopper is a notable inventor based in Thousand Oaks, California. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target neurodegenerative disorders. With a total of seven patents to his name, Hopper's work is recognized for its potential impact on medical treatments.

Latest Patents

Hopper's latest patents include innovative compounds that act as agonists for the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). These compounds, described in his patent disclosures, are useful for activating TREM2 and are aimed at treating neurodegenerative disorders. The disclosures also detail pharmaceutical compositions that incorporate these compounds, as well as intermediates that are essential for their synthesis.

Career Highlights

Throughout his career, Timothy Hopper has worked with prominent companies in the biotechnology sector. Notably, he has been associated with Amgen Inc. and Vigil Neuroscience, Inc. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.

Collaborations

Hopper has collaborated with several professionals in his field, including Lara C Czabaniuk and Jonathan B Houze. These collaborations have likely enhanced his research and development efforts, leading to the successful creation of his patented compounds.

Conclusion

Timothy Hopper's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a significant inventor. His work continues to pave the way for advancements in the treatment of neurodegenerative disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…